Korean Post-marketing Surveillance for Sprycel®

NCT01464047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 670

Last updated 2016-04-27

No results posted yet for this study

Summary

The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory authority can manage the marketing approval properly.

Conditions

  • Leukemia, Myelomonocytic, Chronic
  • Leukemia-Lymphoma

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01464047 on ClinicalTrials.gov